KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Did you know that certain medications can cause symptom of 'Corneal epithelium defect'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.

In some cases, a therapeutic mechanical debridement of the cornea and the “stalled out” leading epithelial cells is required to encourage epithelial cell migration and adhesion.

The FDA has granted Fast Track designation to KPI-012 for the treatment of persistent corneal epithelial defect.

Shares of Krystal Biotech KRYS gained 3.9% yesterday after the company announced that it had dosed the first patient in a ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

The central four fifths of the left cornea is denuded of epithelium (arrows indicate the margins of the defect), and there is diffuse stromal edema with infiltrates inferonasally.

After the second treatment, the epithelial defect disappeared on day 7 (Fig. 1C), stromal infiltrate was inactive, corneal vascularization was distinctive, and the ulcer healed with a scar and ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...